Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angiotech denied funding after poor revenue performance

This article was originally published in Scrip

Executive Summary

Angiotech Pharmaceuticals, a Canadian pharmaceutical and medical device company, is facing an uncertain future after being unable to secure funding. It has informed potential investors Ares Management and New Leaf Venture Partners that it is unlikely to be able to meet the terms of a proposed deal that would have secured a $200-300 million investment in the company. Angiotech did not have the minimal level of cash and cash equivalents required at the time of the transaction's close. This was largely due to lower than expected revenue fromBoston Scientific, for whom Angiotech makes the coating for drug eluting coronary stents. As a result, the company has increased reorganisational efforts that were announced in April. These include the closure of its research and manufacturing facility in Rochester, New York, postponement of certain preclinical-stage research activities and the reduction of certain financial and personnel contributions relating to its joint venture withGenzyme. Angiotech's share price dropped below $1 after the announcement and closed at just $0.59 on September 23rd.

You may also be interested in...



Myotec and Hybrid merge to form PsiOxus

Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.

Trophos's MitoCare programme receives €6 million EU funding

A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.

Novartis and Alcon reach compromise to settle merger saga

Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel